OCT 22, 2020 1:35 PM SGT

Latest Developments with the Genexus System

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Medical Director, Thermo Fisher Scientific
    Biography

      José Luis Costa carried out his undergraduate studies at the University of Porto in Portugal and obtained his Ph.D. degree in Biology at Uppsala University in Sweden. Prior to joining the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) in 2006, he carried out postdoctoral research at the Vrije University Medical Center in Amsterdam, The Netherlands. He was appointed, in 2014, as Affiliated Professor at the Medical Faculty of the University of Porto. In 2020, joined Thermo Fisher Scientific as EMEA Medical Affairs Director part of the Clinical NGS and Oncology Division. Throughout his career he seeks to promote the uptake of Precision Medicine for the benefit of patients through the application of the latest technologies in the diagnosis and the search for precision therapies.


    Abstract

    The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more effective targeted cancer therapies. Considering these advances, the testing of molecular biomarkers for cancer patient stratification has become mandatory. Such tests are performed routinely using biopsy/cytology material from primary tumors obtained at the time of diagnosis. Next generation sequencing solution presents several advantages and current guidelines suggest NGS as first line molecular test to be performed. An additional aspect to consider is time to result. Any test is only effective is it provides its information in time to be considered for medical intervention. In particular, cancer molecular testing where the time window to initiate treatment are days. Here we will discuss the Ion Torrent Genexus System, the first turnkey NGS solution that automates the specimen-to-report workflow and can deliver results in a single day. This talk will focus on different aspects surrounding the system, from technological developments to analytical validation and clinical implementation.

     

    Learning Objectives:

    1. The importance of biomarker testing for precision medicine

    2. How to implement biomarker using next generation sequencing


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    MAR 30, 2021 8:00 AM PDT
    MAR 30, 2021 8:00 AM PDT
    DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    Loading Comments...
    Show Resources